FTSE MIB
33.799,72 +170,51 (+0,51%) Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,82 +0,71 (+0,91%) Bitcoin EUR
59.807,64 +471,88 (+0,80%)
ImmuCell Corporation (ICCC)
| Chiusura precedente | 5,01 |
| Aperto | 5,02 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 5,00 - 5,14 |
| Intervallo di 52 settimane | 4,26 - 6,05 |
| Volume | |
| Media Volume | 7.596 |
| Capitalizzazione | 39,356M |
| Beta (5 anni mensile) | 0,60 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,75 |
| Prossima data utili | 09 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023. Preliminary, Unaudited Total Sales Results: 20232022$ Increase ($ Decrease) % Incr
- GlobeNewswire
ImmuCell Announces Submission of CMC Technical Section to the FDA
PORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA. On August 10, 2023, the Company issued a disclosure stating that
- GlobeNewswire
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023. Management’s Discussion: “Our unaudited, preliminary product sales were first reported on July 11, 2023,” comment
